Please login to the form below

Not currently logged in
Email:
Password:

Santarus adds two board members

Alessandro Della Chà and Dr Matthew Strobeck join US biopharma

Santarus has appointed Alessandro Della Chà and Dr Matthew Strobeck to its board of directors.

The appointments mean the US-based biopharma firm, which has products including Glumetza (metformin hydrochloride extended release tablets) and Cycloset (bromocriptine mesylate) tablets, has now increased its number of directors to nine.

“We welcome our new board members and look forward to drawing on their industry, business and corporate expertise as we continue to build Santarus into a premier specialty biopharmaceutical company,” said David Hale, chair of Santarus.

Della Chà has been a senior partner of Italian commercial law firm Studio Legale Edoardo Ricci e Associati, since 1997. He has also been co-managing director of the company since 2003. He currently also serves as a director of Cosmo Pharmaceuticals.

Dr Strobeck was a partner, member of the management committee and member of the advisory board of Westfield Capital Management from 2008 to 2011. He currently serves as a member of the board of directors of Metabolix.

11th April 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...
MIT reveals new pill to deliver insulin
A new MIT research project, sponsored by Novo Nordisk, is aiming to deliver insulin orally with a pill that releases medicine in the stomach lining. Dina Patel interviews the team...
Fearless Girl cover
25 Women Leaders in UK Healthcare
Women trailblazers helping to shape the future of healthcare (Part 1)...

Infographics